Mechanisms underlying dilated cardiomyopathy associated with FKBP12 deficiency

Amy D Hanna1, Ting Chang1, Kevin S Ho1

  • 1Department of Integrative Physiology, Baylor College of Medicine, Houston, TX, USA.

PubMed

Insights

FKBP12 deficiency during early embryonic development causes dilated cardiomyopathy (DCM) in mice. This leads to cardiac remodeling, oxidative stress, and impaired heart function, highlighting FKBP12

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Dilated cardiomyopathy (DCM) is a prevalent heart condition with genetic heterogeneity, affecting cardiac contractility.
  • The role of FK506-binding protein FKBP12 in cardiac muscle function is not well understood, despite its known role in skeletal muscle ryanodine receptor regulation.

Purpose of the Study:

  • To investigate the specific role of FKBP12 in cardiac function and its potential involvement in the pathogenesis of DCM.
  • To determine the impact of FKBP12 deficiency on cardiac remodeling, oxidative stress, and calcium handling in the heart.

Main Methods:

  • Generation of conditional mouse models with FKBP12 deficiency using Cre-lox technology driven by cardiac-specific promoters (αMHC and MCK).
  • Analysis of cardiac function, histology, protein expression, and sarcoplasmic reticulum Ca2+ leak in adult mice with FKBP12 deletion at different embryonic stages.

Main Results:

  • Conditional deletion of FKBP12 in adult hearts did not cause significant cardiac dysfunction.
  • Early embryonic deletion of FKBP12 (αMHC-Cre) led to progressive DCM, increased cardiac oxidative stress, altered expression of cardiac remodeling proteins, and sarcoplasmic reticulum Ca2+ leak.
  • FKBP12 deficiency during early development, but not later, resulted in significant cardiac pathology.

Conclusions:

  • FKBP12 plays a critical role in embryonic cardiac muscle development and function.
  • Early developmental deficiency of FKBP12 leads to cardiac remodeling and progressive DCM in adult hearts.
  • These findings suggest FKBP12 as a potential therapeutic target for preventing or treating DCM associated with early developmental defects.